We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TMO Stock May Benefit From New Gibco CTS Portfolio Addition
Read MoreHide Full Article
Key Takeaways
Thermo Fisher launched Gibco CTS Compleo, an automated fill-finish system for cell therapy workflows.
TMO's system reduces manual steps, improves consistency and supports faster therapy delivery.
The growing cell therapy market and CTS portfolio expansion strengthen Thermo Fisher's position.
Thermo Fisher Scientific (TMO - Free Report) announced the global rollout of the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing. The System is part of the growing Gibco Cell Therapy Systems (“CTS”) portfolio designed to support cell therapy manufacturers with instruments, consumables and software, GMP-manufactured media and reagents and viral vector systems.
The company is set to showcase the CTS Compleo system and Gibco CTS portfolio at the International Society for Cell & Gene Therapy and the American Society of Gene & Cell Therapy annual meetings in May.
TMO Stock Outlook Following the News
Following the April 2 announcement, TMO shares have dropped 0.7%, closing at $488.19 yesterday. On a promising note, Thermo Fisher’s latest development addresses one of the biggest challenges in cell therapy manufacturing, manual fill and finish. The Gibco CTS Compleo system combines automation with a functionally closed design to streamline workflows, improve consistency and help accelerate the delivery of life-changing therapies. We expect the news to help support a rebound of TMO stock.
Thermo Fisher is currently valued at $182.57 billion. The company’s earnings yield of 5.02% favorably compares to the industry’s negative 1.8% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.8%.
Importance of Thermo Fisher’s New Launch
Cell therapies often begin with patient-derived cells, requiring manufacturing workflows to accommodate variability in cell count, concentration and viability. With more therapies moving toward commercialization, manufacturers are looking to cut manual intervention and improve operational efficiency while managing strict standards for sterility, dose accuracy and product consistency.
Image Source: Zacks Investment Research
Formulation and filling have been traditionally performed using manual methods, requiring careful handling of fragile cells in small volumes, introducing variability and risk of contamination. The company’s CTS Compleo system offers a compact, automated, functionally closed solution for formulation and filling, helping reduce manual intervention and supporting consistent batch-to-batch performance. Early collaborators have reported benefits from using the advanced technology in the CTS Compleo system to reduce variability and streamline cell therapy manufacturing.
All of the company’s Gibco CTS portfolio solutions, along with the Gibco PeproGMP growth factors and cytokines, are helping enable GMP-compliant, closed-system manufacturing and allow for physical and digital integration across the workflow.
Industry Prospects Favor Thermo Fisher
According to the Precedence Research report, the global cell therapy manufacturing market was valued at $4.83 billion in 2024 and is projected to witness a CAGR of 14.6% through 2034. Some of the key factors driving growth are the rising cases of chronic diseases such as cancer, autoimmune disorders and degenerative conditions.
Over the past decade, multiple cell therapies have secured regulatory approvals and delivered meaningful outcomes for patients with limited treatment options. These developments have validated the therapeutic potential of cell-based interventions, and attracted public and private investment.
More Updates From Thermo Fisher
The company recently introduced the Gibco CHOvantage GS Cell Line Development Kit, a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability. Another launch, the Thermo Scientific Glacios 3 cryogenic transmission electron microscope, is designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before.
TMO Stock Price Performance
Over the past year, TMO shares have risen 16.4% compared with the industry’s 8.4% growth.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
BrightSpring Health Services shares have soared 165.4% in the past year. Estimates for the company’s 2026 EPS have jumped 15% to $1.61 in the past 60 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%. It has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth.
Globus Medical shares have risen 29.1% in the past year. Estimates for the company’s 2026 EPS have increased 14.7% to $4.46 in the past 60 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%. In the last reported quarter, it posted an earnings surprise of 20.8%.
Estimates for IDEXX Laboratories’ 2026 EPS have increased 0.6% in the past 60 days. Shares of the company have surged 60.1% in the past year compared with the industry’s 8.4% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.1%. In the last reported quarter, it delivered an earnings surprise of 5.1%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
TMO Stock May Benefit From New Gibco CTS Portfolio Addition
Key Takeaways
Thermo Fisher Scientific (TMO - Free Report) announced the global rollout of the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing. The System is part of the growing Gibco Cell Therapy Systems (“CTS”) portfolio designed to support cell therapy manufacturers with instruments, consumables and software, GMP-manufactured media and reagents and viral vector systems.
The company is set to showcase the CTS Compleo system and Gibco CTS portfolio at the International Society for Cell & Gene Therapy and the American Society of Gene & Cell Therapy annual meetings in May.
TMO Stock Outlook Following the News
Following the April 2 announcement, TMO shares have dropped 0.7%, closing at $488.19 yesterday. On a promising note, Thermo Fisher’s latest development addresses one of the biggest challenges in cell therapy manufacturing, manual fill and finish. The Gibco CTS Compleo system combines automation with a functionally closed design to streamline workflows, improve consistency and help accelerate the delivery of life-changing therapies. We expect the news to help support a rebound of TMO stock.
Thermo Fisher is currently valued at $182.57 billion. The company’s earnings yield of 5.02% favorably compares to the industry’s negative 1.8% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.8%.
Importance of Thermo Fisher’s New Launch
Cell therapies often begin with patient-derived cells, requiring manufacturing workflows to accommodate variability in cell count, concentration and viability. With more therapies moving toward commercialization, manufacturers are looking to cut manual intervention and improve operational efficiency while managing strict standards for sterility, dose accuracy and product consistency.
Image Source: Zacks Investment Research
Formulation and filling have been traditionally performed using manual methods, requiring careful handling of fragile cells in small volumes, introducing variability and risk of contamination. The company’s CTS Compleo system offers a compact, automated, functionally closed solution for formulation and filling, helping reduce manual intervention and supporting consistent batch-to-batch performance. Early collaborators have reported benefits from using the advanced technology in the CTS Compleo system to reduce variability and streamline cell therapy manufacturing.
All of the company’s Gibco CTS portfolio solutions, along with the Gibco PeproGMP growth factors and cytokines, are helping enable GMP-compliant, closed-system manufacturing and allow for physical and digital integration across the workflow.
Industry Prospects Favor Thermo Fisher
According to the Precedence Research report, the global cell therapy manufacturing market was valued at $4.83 billion in 2024 and is projected to witness a CAGR of 14.6% through 2034. Some of the key factors driving growth are the rising cases of chronic diseases such as cancer, autoimmune disorders and degenerative conditions.
Over the past decade, multiple cell therapies have secured regulatory approvals and delivered meaningful outcomes for patients with limited treatment options. These developments have validated the therapeutic potential of cell-based interventions, and attracted public and private investment.
More Updates From Thermo Fisher
The company recently introduced the Gibco CHOvantage GS Cell Line Development Kit, a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability. Another launch, the Thermo Scientific Glacios 3 cryogenic transmission electron microscope, is designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before.
TMO Stock Price Performance
Over the past year, TMO shares have risen 16.4% compared with the industry’s 8.4% growth.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Globus Medical (GMED - Free Report) and IDEXX Laboratories (IDXX - Free Report) . While BTSG and GMED each sport a Zacks Rank #1 (Strong Buy), IDXX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring Health Services shares have soared 165.4% in the past year. Estimates for the company’s 2026 EPS have jumped 15% to $1.61 in the past 60 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%. It has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth.
Globus Medical shares have risen 29.1% in the past year. Estimates for the company’s 2026 EPS have increased 14.7% to $4.46 in the past 60 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%. In the last reported quarter, it posted an earnings surprise of 20.8%.
Estimates for IDEXX Laboratories’ 2026 EPS have increased 0.6% in the past 60 days. Shares of the company have surged 60.1% in the past year compared with the industry’s 8.4% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.1%. In the last reported quarter, it delivered an earnings surprise of 5.1%.